Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours.

ABSTRACT:

Background

Peptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours (GEP NETs), Although Phase III randomised clinical trial data is not available for NETs of other site of origin, in practice, PRRT is used more widely in clinical practice, based on its mechanism of targeting the somatostatin receptor. Use of PRRT for lung (bronchial) NET, specifically typical and atypical carcinoid (TC, AC), has been reported only in small retrospective case series. This multicentre study adds to the evidence regarding utility of PRRT for lung NETs.

Materials and methods

A retrospective chart review of patients with TC and AC who received ¹⁷⁷Lu-dotatate PRRT between January 2002 and June 2019 in six hospitals

SUBMITTER: Lim LE 

PROVIDER: S-EPMC7343632 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature